305 related articles for article (PubMed ID: 1798701)
1. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.
Kettleborough CA; Saldanha J; Heath VJ; Morrison CJ; Bendig MM
Protein Eng; 1991 Oct; 4(7):773-83. PubMed ID: 1798701
[TBL] [Abstract][Full Text] [Related]
2. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies.
Kolbinger F; Saldanha J; Hardman N; Bendig MM
Protein Eng; 1993 Nov; 6(8):971-80. PubMed ID: 8309946
[TBL] [Abstract][Full Text] [Related]
3. Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions.
Sato K; Tsuchiya M; Saldanha J; Koishihara Y; Ohsugi Y; Kishimoto T; Bendig MM
Mol Immunol; 1994 Apr; 31(5):371-81. PubMed ID: 8152440
[TBL] [Abstract][Full Text] [Related]
4. Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions.
Ohtomo T; Tsuchiya M; Sato K; Shimizu K; Moriuchi S; Miyao Y; Akimoto T; Akamatsu K; Hayakawa T; Ohsugi Y
Mol Immunol; 1995 Apr; 32(6):407-16. PubMed ID: 7753049
[TBL] [Abstract][Full Text] [Related]
5. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
Mateo C; Moreno E; Amour K; Lombardero J; Harris W; Pérez R
Immunotechnology; 1997 Mar; 3(1):71-81. PubMed ID: 9154469
[TBL] [Abstract][Full Text] [Related]
6. Cloning of cDNAs encoding the variable domains of antibody KC4G3 and construction of a chimeric antibody.
Couto JR; Blank EW; Peterson JA; Ceriani RL
Hybridoma; 1993 Aug; 12(4):485-9. PubMed ID: 8244420
[TBL] [Abstract][Full Text] [Related]
7. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
Wu H; Nie Y; Huse WD; Watkins JD
J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
[TBL] [Abstract][Full Text] [Related]
8. Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.
Batra SK; Niswonger ML; Wikstrand CJ; Pegram CN; Zalutsky MR; Morrison SL; Bigner DD
Hybridoma; 1994 Apr; 13(2):87-97. PubMed ID: 8050781
[TBL] [Abstract][Full Text] [Related]
9. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
[TBL] [Abstract][Full Text] [Related]
10. Cloning of cDNAs encoding the variable domains of antibody BrE-3 and construction of a chimeric antibody.
Couto JR; Blank EW; Peterson JA; Ceriani RL
Hybridoma; 1993 Feb; 12(1):15-23. PubMed ID: 8454302
[TBL] [Abstract][Full Text] [Related]
11. Idiotope determining regions of a mouse monoclonal antibody and its humanized versions. Identification of framework residues that affect idiotype expression.
Corti A; Barbanti E; Tempest PR; Carr FJ; Marcucci F
J Mol Biol; 1994 Jan; 235(1):53-60. PubMed ID: 8289265
[TBL] [Abstract][Full Text] [Related]
12. Construction and expression of two mouse-human chimeric antibodies with high specificity and affinity for carcinoembryonic antigen.
Arakawa F; Haruno M; Kuroki M; Kanda H; Watanabe T; Misumi Y; Matsuoka Y
Hybridoma; 1993 Aug; 12(4):365-79. PubMed ID: 8244416
[TBL] [Abstract][Full Text] [Related]
13. Antibody framework residues affecting the conformation of the hypervariable loops.
Foote J; Winter G
J Mol Biol; 1992 Mar; 224(2):487-99. PubMed ID: 1560463
[TBL] [Abstract][Full Text] [Related]
14. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
15. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
16. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Feb; 96(2):381-91. PubMed ID: 16937408
[TBL] [Abstract][Full Text] [Related]
17. Efficient generation of a reshaped human mAb specific for the alpha toxin of Clostridium perfringens.
Tempest PR; White P; Williamson ED; Titball RW; Kelly DC; Kemp GJ; Gray PM; Forster SJ; Carr FJ; Harris WJ
Protein Eng; 1994 Dec; 7(12):1501-7. PubMed ID: 7716162
[TBL] [Abstract][Full Text] [Related]
18. Construction of reshaped human antibodies with HIV-neutralizing activity.
Maeda H; Matsushita S; Eda Y; Kimachi K; Tokiyoshi S; Bendig MM
Hum Antibodies Hybridomas; 1991 Jul; 2(3):124-34. PubMed ID: 1873503
[TBL] [Abstract][Full Text] [Related]
19. Chimeric and humanized antibodies with specificity for the CD33 antigen.
Co MS; Avdalovic NM; Caron PC; Avdalovic MV; Scheinberg DA; Queen C
J Immunol; 1992 Feb; 148(4):1149-54. PubMed ID: 1737932
[TBL] [Abstract][Full Text] [Related]
20. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing.
Roguska MA; Pedersen JT; Henry AH; Searle SM; Roja CM; Avery B; Hoffee M; Cook S; Lambert JM; Blättler WA; Rees AR; Guild BC
Protein Eng; 1996 Oct; 9(10):895-904. PubMed ID: 8931129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
